KOSDAQ: 095700

South Korea-based Genexine (KOSDAQ: 095700) has announced that its long-acting growth hormone product candidate, eftansomatropin alfa (GX-H9; TJ101), has achieved Phase III endpoints in a clinical trial conducted in China. The study, CTJ101PGHD301, demonstrated the safety and efficacy of the drug in children with growth hormone deficiency. Eftansomatropin Alfa’s Efficacy…